Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLC

The impact of selpercatinib in patients with RET fusion-positive NSCLCПодробнее

RET fusion-positive mNSCLC: selpercatinib and pralsetinibПодробнее

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid c...Подробнее

FDA approval of selpercatinib for RET fusion positive NSCLC and thyroid cancersПодробнее

[lung] Effect of selpercatinib for RET-positive patientsПодробнее

Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 studyПодробнее

Updated overall efficacy and safety of selpercatinib in patients with RET fusion+ NSCLCПодробнее

Intracranial activity of selpercatinib in RET fusion positive NSCLCПодробнее

RET Fusion Treatment: Selpercatinib - Targeted Therapies in Lung Cancer 2023Подробнее

Pralsetinib in Chinese patients with advanced RET fusion+ NSCLCПодробнее

[lung] Selpercatinib is also effective against brain metastasis.Подробнее

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLCПодробнее

Selpercatinib approved for treatment of tumours harbouring RET gene fusions #cancer #selpercatinibПодробнее

Rare Fusions in NSCLC: RET - Targeted Therapies in Lung Cancer 2023Подробнее

LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLCПодробнее

Emerging Agents and Combinations to Treat RET Fusion-Positive Lung CancersПодробнее

Selpercatinib in RET-altered Thyroid Cancers with Dr. Lori WirthПодробнее

Selpercatinib and Pralsetinib for RET Fusions - 2025 Targeted Therapies in Lung Cancer Patient ForumПодробнее

Dr Somnath Roy | Durability of Efficacy and Safety with Selpercatinib in Patients with RET FusionПодробнее